Small Cell Lung Cancer
The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.
The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.
Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.
The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.
Surgery for early stage small cell lung cancer (SCLC) is rarely used. However, results from a population-based database has shown surgery with adjuvant chemotherapy with or without radiation for node-negative SCLC was associated with better survival compared with concurrent chemoradiation, according to a presentation at the 2016 ASCO Annual Meeting.
Chemotherapy, with or without cranial irradiation, has been associated with improved survival versus surgery alone for patients with early-stage small-cell lung cancer (SCLC) undergoing resection.
Chemotherapy use associated with a survival benefit for Medicare patients with small cell lung cancer (SCLC) treated in a real-world setting.
Chemotherapy can improve median survival by more than 6 months in elderly persons with small cell lung cancer (SCLC), a retrospective cohort study has indicated.
A histology-expression predictor has been developed for the most common types of lung cancer and can corroborate the findings of pathologists.
Persons with limited-stage small cell lung cancer (LS-SCLC) exhibited better disease control and survival when staged with positron emission tomography (PET) than did patients who did not undergo staging with PET.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
An analysis of breath samples from patients with pulmonary nodules distinguished benign from malignant growths in a recent study.
PARP1 and EZH2 may be treatment targets in small cell lung cancer, based on newfound differences between this and non-small cell disease.
Small cell lung cancers have high expression of PARP1; are more sensitive to PARP inhibition.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|